Pharmaceutical

Agenus gets grant for monoclonal antibodies targeting TIM-3 for treating subjects

Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.

May 3, 2024 - 00:00
Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.
Read the original article

Tags:

Previous Article

Astellas Pharma gets grant for novel carbocyclic prolinamide derivatives for tre...

Next Article

Variety in building block softness makes for softer amorphous materials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023

ESCMID 2024: Drug resistance in fungi – a growing issue

ESCMID 2024: Drug resistance in fungi – a growing issue

May 3, 2024

Opinion: Starting breast cancer screening at 40 saved my life

Opinion: Starting breast cancer screening at 40 saved m...

May 17, 2023